Cargando…
Treatment of hepatocellular carcinoma with hepatic vein tumor thrombosis protruding into the inferior vena cava by conversion surgery following chemotherapy with regorafenib: a case report
Regorafenib is an oral multikinase inhibitor affecting angiogenesis, oncogenesis, metastasis, and tumor immunity. As a systemic treatment, it has been shown to provide survival benefits in hepatocellular carcinoma (HCC) patients progressing on sorafenib treatment. We report herein a case of HCC with...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239798/ https://www.ncbi.nlm.nih.gov/pubmed/31970661 http://dx.doi.org/10.1007/s12328-019-01077-4 |
_version_ | 1783536750909456384 |
---|---|
author | Takeda, Kazuhisa Tsurumaru, Yuji Yamamoto, Yuji Araki, Kentaro Kogure, Yu Mori, Koichi Nakagawa, Kazuya Shimizu, Tetsuya Matsuda, Goro Niino, Hitoshi Sekido, Hitoshi Kobayashi, Satoshi Morimoto, Manabu Kunisaki, Chikara Endo, Itaru |
author_facet | Takeda, Kazuhisa Tsurumaru, Yuji Yamamoto, Yuji Araki, Kentaro Kogure, Yu Mori, Koichi Nakagawa, Kazuya Shimizu, Tetsuya Matsuda, Goro Niino, Hitoshi Sekido, Hitoshi Kobayashi, Satoshi Morimoto, Manabu Kunisaki, Chikara Endo, Itaru |
author_sort | Takeda, Kazuhisa |
collection | PubMed |
description | Regorafenib is an oral multikinase inhibitor affecting angiogenesis, oncogenesis, metastasis, and tumor immunity. As a systemic treatment, it has been shown to provide survival benefits in hepatocellular carcinoma (HCC) patients progressing on sorafenib treatment. We report herein a case of HCC with hepatic vein tumor thrombosis protruding into the inferior vena cava (IVC-HVTT) which was successfully treated by surgery following second-line chemotherapy with regorafenib. A 79-year-old man with chronic hepatitis was diagnosed with HCC. Computed tomography revealed a solitary tumor in segments 7 and 8 and an IVC-HVTT from the right hepatic vein. Since IVC-HVTT removal is a difficult procedure, the tumor was diagnosed as unresectable, and administration of sorafenib was started. Five weeks later, the lesion had increased in size by 15.3%; subsequently, regorafenib was given as second-line therapy for 12 months. After shrinkage of the IVC-HVTT, the patient was referred to our hospital for surgery. One month after the cessation of regorafenib, an extended resection of segment 8 and total removal of the IVC-HVTT was successfully performed without using total hepatic vascular exclusion. There were no serious postoperative complications. Additionally, there has been no recurrence for about 2 years since the initial therapy. |
format | Online Article Text |
id | pubmed-7239798 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-72397982020-05-27 Treatment of hepatocellular carcinoma with hepatic vein tumor thrombosis protruding into the inferior vena cava by conversion surgery following chemotherapy with regorafenib: a case report Takeda, Kazuhisa Tsurumaru, Yuji Yamamoto, Yuji Araki, Kentaro Kogure, Yu Mori, Koichi Nakagawa, Kazuya Shimizu, Tetsuya Matsuda, Goro Niino, Hitoshi Sekido, Hitoshi Kobayashi, Satoshi Morimoto, Manabu Kunisaki, Chikara Endo, Itaru Clin J Gastroenterol Case Report Regorafenib is an oral multikinase inhibitor affecting angiogenesis, oncogenesis, metastasis, and tumor immunity. As a systemic treatment, it has been shown to provide survival benefits in hepatocellular carcinoma (HCC) patients progressing on sorafenib treatment. We report herein a case of HCC with hepatic vein tumor thrombosis protruding into the inferior vena cava (IVC-HVTT) which was successfully treated by surgery following second-line chemotherapy with regorafenib. A 79-year-old man with chronic hepatitis was diagnosed with HCC. Computed tomography revealed a solitary tumor in segments 7 and 8 and an IVC-HVTT from the right hepatic vein. Since IVC-HVTT removal is a difficult procedure, the tumor was diagnosed as unresectable, and administration of sorafenib was started. Five weeks later, the lesion had increased in size by 15.3%; subsequently, regorafenib was given as second-line therapy for 12 months. After shrinkage of the IVC-HVTT, the patient was referred to our hospital for surgery. One month after the cessation of regorafenib, an extended resection of segment 8 and total removal of the IVC-HVTT was successfully performed without using total hepatic vascular exclusion. There were no serious postoperative complications. Additionally, there has been no recurrence for about 2 years since the initial therapy. Springer Singapore 2020-01-22 2020 /pmc/articles/PMC7239798/ /pubmed/31970661 http://dx.doi.org/10.1007/s12328-019-01077-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Case Report Takeda, Kazuhisa Tsurumaru, Yuji Yamamoto, Yuji Araki, Kentaro Kogure, Yu Mori, Koichi Nakagawa, Kazuya Shimizu, Tetsuya Matsuda, Goro Niino, Hitoshi Sekido, Hitoshi Kobayashi, Satoshi Morimoto, Manabu Kunisaki, Chikara Endo, Itaru Treatment of hepatocellular carcinoma with hepatic vein tumor thrombosis protruding into the inferior vena cava by conversion surgery following chemotherapy with regorafenib: a case report |
title | Treatment of hepatocellular carcinoma with hepatic vein tumor thrombosis protruding into the inferior vena cava by conversion surgery following chemotherapy with regorafenib: a case report |
title_full | Treatment of hepatocellular carcinoma with hepatic vein tumor thrombosis protruding into the inferior vena cava by conversion surgery following chemotherapy with regorafenib: a case report |
title_fullStr | Treatment of hepatocellular carcinoma with hepatic vein tumor thrombosis protruding into the inferior vena cava by conversion surgery following chemotherapy with regorafenib: a case report |
title_full_unstemmed | Treatment of hepatocellular carcinoma with hepatic vein tumor thrombosis protruding into the inferior vena cava by conversion surgery following chemotherapy with regorafenib: a case report |
title_short | Treatment of hepatocellular carcinoma with hepatic vein tumor thrombosis protruding into the inferior vena cava by conversion surgery following chemotherapy with regorafenib: a case report |
title_sort | treatment of hepatocellular carcinoma with hepatic vein tumor thrombosis protruding into the inferior vena cava by conversion surgery following chemotherapy with regorafenib: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239798/ https://www.ncbi.nlm.nih.gov/pubmed/31970661 http://dx.doi.org/10.1007/s12328-019-01077-4 |
work_keys_str_mv | AT takedakazuhisa treatmentofhepatocellularcarcinomawithhepaticveintumorthrombosisprotrudingintotheinferiorvenacavabyconversionsurgeryfollowingchemotherapywithregorafenibacasereport AT tsurumaruyuji treatmentofhepatocellularcarcinomawithhepaticveintumorthrombosisprotrudingintotheinferiorvenacavabyconversionsurgeryfollowingchemotherapywithregorafenibacasereport AT yamamotoyuji treatmentofhepatocellularcarcinomawithhepaticveintumorthrombosisprotrudingintotheinferiorvenacavabyconversionsurgeryfollowingchemotherapywithregorafenibacasereport AT arakikentaro treatmentofhepatocellularcarcinomawithhepaticveintumorthrombosisprotrudingintotheinferiorvenacavabyconversionsurgeryfollowingchemotherapywithregorafenibacasereport AT kogureyu treatmentofhepatocellularcarcinomawithhepaticveintumorthrombosisprotrudingintotheinferiorvenacavabyconversionsurgeryfollowingchemotherapywithregorafenibacasereport AT morikoichi treatmentofhepatocellularcarcinomawithhepaticveintumorthrombosisprotrudingintotheinferiorvenacavabyconversionsurgeryfollowingchemotherapywithregorafenibacasereport AT nakagawakazuya treatmentofhepatocellularcarcinomawithhepaticveintumorthrombosisprotrudingintotheinferiorvenacavabyconversionsurgeryfollowingchemotherapywithregorafenibacasereport AT shimizutetsuya treatmentofhepatocellularcarcinomawithhepaticveintumorthrombosisprotrudingintotheinferiorvenacavabyconversionsurgeryfollowingchemotherapywithregorafenibacasereport AT matsudagoro treatmentofhepatocellularcarcinomawithhepaticveintumorthrombosisprotrudingintotheinferiorvenacavabyconversionsurgeryfollowingchemotherapywithregorafenibacasereport AT niinohitoshi treatmentofhepatocellularcarcinomawithhepaticveintumorthrombosisprotrudingintotheinferiorvenacavabyconversionsurgeryfollowingchemotherapywithregorafenibacasereport AT sekidohitoshi treatmentofhepatocellularcarcinomawithhepaticveintumorthrombosisprotrudingintotheinferiorvenacavabyconversionsurgeryfollowingchemotherapywithregorafenibacasereport AT kobayashisatoshi treatmentofhepatocellularcarcinomawithhepaticveintumorthrombosisprotrudingintotheinferiorvenacavabyconversionsurgeryfollowingchemotherapywithregorafenibacasereport AT morimotomanabu treatmentofhepatocellularcarcinomawithhepaticveintumorthrombosisprotrudingintotheinferiorvenacavabyconversionsurgeryfollowingchemotherapywithregorafenibacasereport AT kunisakichikara treatmentofhepatocellularcarcinomawithhepaticveintumorthrombosisprotrudingintotheinferiorvenacavabyconversionsurgeryfollowingchemotherapywithregorafenibacasereport AT endoitaru treatmentofhepatocellularcarcinomawithhepaticveintumorthrombosisprotrudingintotheinferiorvenacavabyconversionsurgeryfollowingchemotherapywithregorafenibacasereport |